During the past trading week (October 7 to 11), an executive for a US-based cannabis firm said he held meetings with exchange regulators to discuss the possibility of an update to current listing requirements.

Also making headlines was the cancellation of two significant deals in the public marijuana space, as well as the poor performance of a Canadian cannabis stock due to recent changes.


Here’s a closer look at some of the biggest cannabis news over the last week.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Curaleaf asks for regulation adjustment to benefit MSOs

During a recent investor event in Toronto, Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) Chairman Boris Jordan said he had met with executives of the TMX Group, the NASDAQ and New York Stock Exchange to ask for a change in the ruling currently preventing the listing of marijuana multi-state operators (MSOs) in the US.

These senior listings would offer a boost to the firms, which many investors have expressed interest in. However, due to the federal illegality of the drug in the states, companies are still prohibited from listing. This doesn’t include exchanges that have allowed it, like the Canadian Securities Exchange (CSE) and the NEO Exchange.

A TMX spokesperson would not confirm or deny the existence of the meeting to the Investing News Network (INN), but admitted it regularly monitors the legislation for the marijuana sector.

In a statement to INN, the MSO said it “routinely meets with members of the financial community. This includes representatives from stock exchanges regarding ways to increase accessibility and liquidity for investors.”

Elliot Johnson, chief investment officer and chief operating officer at Evolve Funds Group, told INN a shift in the ruling from the TMX would give it a great benefit in comparison to the senior American exchanges.

“I think they would rather take them now than wait until the law changes in the States and have those companies move down to the NYSE,” Johnson said. “The TSX needs to compete and they’re maybe needing to play catch up.”

HEXO investors take a hit

During the past trading week, shareholders of Quebec-based cannabis producer HEXO (NYSE:HEXO,TSX:HEXO) felt the pressure of the market as the firm faced two critical developments.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The marijuana firm was forced to revisit its financial projection for its 2020 fiscal outlook. Yearly net revenue is now projected to be between C$46.5 million and C$48.5 million. Sebastien St-Louis, HEXO CEO, had previously stated the revenues in Q4 would double the nearly C$13 million generated during Q3.

“Given the uncertainties in the marketplace, we have determined that it is the appropriate course of action. We are also placing a greater focus on profitability. We are evaluating our plans and operations to see where we can be even more efficient,” said St-Louis.

After it was announced its CFO Michael Monahan would step away from his role at HEXO, an analyst in the US used the shift as a way to downgrade his rating of the company.

“We think it’s reasonable to assume the corporate finance organization was less developed than what Monahan had realized, perhaps indicating there remains much work to professionalizing said organization than what he (or the Street) fully appreciated,” Bank of America Merrill Lynch analyst Christopher Carey wrote in a note, according to a Bloomberg report.

Change of plans for cannabis agreements

On Tuesday (October 8), Aleafia Health (TSX:ALEF,OTCQX:ALEAF) announced it would end a supply deal agreed between its licensed producer subsidiary Emblem and Aphria (NYSE:APHA,TSX:APHA). The deal was terminated since Aphria failed to issue the agreed product, according to Aleafia Health.

“As a large shareholder of Aleafia, Aphria made good faith efforts to ensure continuation of the Agreement understanding it was in the best interest of all parties involved,” Aphria said in a statement.

Aphria was scheduled to deliver 25,000 kilograms of cannabis products in the first year of the total five year deal.

Below the border, MSO MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) informed investors it would drop its planned acquisition of private cannabis firm PharmaCann.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The MedMen executive team argued this deal had changed in value since it was originally agreed upon in October 2018.

“The cannabis sector has evolved tremendously since we first announced the PharmaCann transaction and based on the current macro-environment and future opportunities that exist for our business, we believe it is now in the best interest of our shareholders to deepen, rather than widen, our company’s reach,” MedMen CEO Adam Bierman said.

Market updates

During the past trading week, the Mexican governing party indicated legalization of cannabis is planned for the end of October now. According to a report from Marijuana Moment, Sen. Ricardo Monreal of the MORENA party in Mexico, said the Chamber of Deputies in the country will see a legalization bill this month.

“We’re thinking that we’ll bring the law out, approve it, at the end of October,” Monreal said. “That’s the schedule we have.”

Shares of The Green Organic Dutchman (TGOD) (TSX:TGOD,OTCQX:TGODF) took a big hit last week after the firm issued an update to shareholders saying it would need to pursue additional sources of financing for its operations.

“(TGOD) will prioritize any financing secured to accelerate commercial production in order to ramp-up revenues,” the firm said.

Former British Columbia Premier Christy Clark joined the board of directors for Constellation Brands (NYSE:STZ) and commented on the performance of Canopy Growth (NYSE:CGC,TSX:WEED) as an investment for the alcohol firm.

“There aren’t really any other companies in the cannabis space at the moment that have this level of capacity,” the ex-politician told BNN Bloomberg.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.

Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.

Keep reading... Show less

The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement

Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination

Keep reading... Show less

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising

Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.

Keep reading... Show less

Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.

Keep reading... Show less